Literature DB >> 23653072

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making.

F Ferrara, G Barosi, A Venditti, E Angelucci, M Gobbi, F Pane, P Tosi, P Zinzani, S Tura.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23653072     DOI： 10.1038/leu.2012.303

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply.

Authors:  Richard M Stone; Coleman Lindsley
Journal:  Haematologica       Date:  2018-11       Impact factor: 9.941

2.  Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.

Authors:  Evan C Chen; Yiwen Liu; Courtney E Harris; Eric S Winer; Martha Wadleigh; Andrew A Lane; Rahul S Vedula; R Coleman Lindsley; Kevin M Copson; Anne Charles; Francisco Marty; Donna Neuberg; Daniel J DeAngelo; Richard M Stone; Marlise R Luskin; Nicolas C Issa; Jacqueline S Garcia
Journal:  Leuk Lymphoma       Date:  2022-03-15

Review 3.  Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

4.  Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country.

Authors:  Sumeet Mirgh; Archana Sharma; Mohammad Rizwan Mohammad Anwar Shaikh; Kirti Kadian; Narendra Agrawal; Vishvdeep Khushoo; Pallavi Mehta; Rayaz Ahmed; Dinesh Bhurani
Journal:  Am J Blood Res       Date:  2021-06-15

5.  Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.

Authors:  J Erika Haydu; Yael Flamand; Rahul S Vedula; Jurjen Versluis; Anne Charles; Kevin M Copson; Richard M Stone; Daniel J DeAngelo; Donna Neuberg; R Coleman Lindsley; Marlise R Luskin
Journal:  Am J Hematol       Date:  2021-04-24       Impact factor: 10.047

Review 6.  New Treatment Options for Older Patients with Acute Myeloid Leukemia.

Authors:  Kapil Saxena; Marina Konopleva
Journal:  Curr Treat Options Oncol       Date:  2021-03-20

Review 7.  Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Front Oncol       Date:  2015-12-14       Impact factor: 6.244

8.  All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Authors:  Fabio Forghieri; Sara Bigliardi; Chiara Quadrelli; Monica Morselli; Leonardo Potenza; Ambra Paolini; Elisabetta Colaci; Patrizia Barozzi; Patrizia Zucchini; Giovanni Riva; Daniela Vallerini; Ivana Lagreca; Roberto Marasca; Franco Narni; Adriano Venditti; Maria Paola Martelli; Brunangelo Falini; Francesco Lo Coco; Sergio Amadori; Mario Luppi
Journal:  Clin Case Rep       Date:  2016-10-24

Review 9.  Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?

Authors:  Felicetto Ferrara; Alessandra Picardi
Journal:  Cancers (Basel)       Date:  2019-12-24       Impact factor: 6.639

Review 10.  An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.

Authors:  Tamer A Othman; Matthew E Tenold; Benjamin N Moskoff; Tali Azenkot; Brian A Jonas
Journal:  Expert Rev Hematol       Date:  2021-06-15       Impact factor: 2.819
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.